Nykode Therapeutics ASA NYKD
OSL · Norway · Health Technology
NOK 3.45-0.12 (-3.36%)
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Nykode Therapeutics AS (VACBF) reports a net loss of $7.2 million in Q2 2026, while advancing its Abili-T trial and leveraging positive industry data to strengthen its cancer vaccine platform.
Despite a widened net loss, Nykode Therapeutics AS (STU:5VB) showcases promising clinical progress and robust financial positioning for future growth.
As European markets navigate the complexities of geopolitical developments and economic shifts, investors are keeping a close eye on potential opportunities within the region. Penny stocks, although an outdated term, continue to offer intriguing possibilities for those interested in smaller or newer companies. When these stocks are backed by strong financial health, they may provide unexpected value and stability.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.